Skip to content

Michael G. Wheaton

2 papers in the library · 85 citations · publishing 2023-2024

Papers

Sort Most recent Most cited

Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder

Psychedelics. September 24, 2024 Xi Zhu, Chen Zhang, David J Hellerstein et al. 6 citations

Body dysmorphic disorder (BDD) is a severe psychiatric condition characterized by preoccupation with perceived flaws in one's appearance, which the individual views as defective or ugly. Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, has emerged as a potential therapeutic agent for depression and other psychiatric disorders. This study aimed to identify subacute neural...

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.

Journal of Psychiatric Research May 1, 2023 Franklin R. Schneier, Jamie D. Feusner, Michael G. Wheaton et al. 79 citations

Body dysmorphic disorder (BDD) is an often-severe condition in which individuals are preoccupied by misperceptions of their appearance as defective or ugly. Only serotonin reuptake inhibitors and cognitive-behavioral therapy have been demonstrated efficacious in randomized controlled trials. Psilocybin is a psychedelic drug with growing evidence for safety and efficacy in treatment of...